Urinary trypsinogen activation peptides (TAP) are not increased in mild ERCP-induced pancreatitis

Pancreas

Volumn 12, Issue 3, 1996, Pages 294-297

  Banks, P A ^a   Carr Locke, D L ^a   Slivka, A ^a   Van Dam, J ^a   Lichtenstein, D R ^a   Hughes, M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute pancreatitis; Endoscopic retrograde cholangiopancreatography induced pancreatitis; Urinary trypsinogen activation peptides

Indexed keywords

TRYPSINOGEN;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; DIAGNOSTIC VALUE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL;

EID: 0029988803     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199604000-00013     Document Type: Article

References (27)

1. Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992;87:1561-6.
2. Rolny P, Anderberg B, Ihse I, Lindstrom E, Olaison G, Arvill A. Pancreatitis after sphincter of Oddi manometry. Gut 1990;31:821-4.
3. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993;54: 105-11.
4. Ferrari AP Jr, Slivka A, Lichtenstein DR, Carr-Locke DL. Factors affecting ERCP complications: looking backwards and forwards. Gastrointest Endosc 1994;40:P20.
5. Cotton PB, Baillie J, Leung J, et al. Correlations with post-ERCP pancreatitis. Gastrointest Endosc 1994;40:P104.
6. Chen YK, Foliente RL, Santoro MJ, Walter MH, Collen MJ. Endoscopic sphincterotomy-induced pancreatitis: increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. Am J Gastroenterol 1994;89:327-33.
7. Smithline A, Silverman W, Rogers D, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopie sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993;39:652-7.
8. Sherman S, Lehman GA. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas 1991;6:350-67.
9. Foitzik T, Lewandrowski KB, Fernandez-del Castillo C, Rattner DW, Warshaw AL. Evidence for extraluminal trypsinogen activation in three different models of acute pancreatitis. Surgery 1994;115:698-702.
10. Grady T, Saluja A, Saluja M, Kaiser A, Steer M. Temporal relationship between trypsinogen activation and the onset of caerulein-induced pancreatitis. Pancreas 1994;9:789.
11. Luthen RE, Woen RL, Sarbia M, Grendell JH, Niederau C. Premature zymogen activation inside pancreatic acinar cells during experimental acute pancreatitis: morphologic evidence by labelling of trypsin activation peptide. Pancreas 1994;9:795.
12. Foitzik T, Schmidt J, Hotz H, Warshaw AL, Buhr HJ, Klar E. Effect of microcirculatory perfusion on distribution of trypsinogen activation peptides in experimental pancreatitis. Int J Pancreatol 1994;16:318.
13. Fernandez-del Castillo C, Schmidt J, Rattner DW, et al. Generation and possible significance of trypsinogen activation peptides in experimental acute pancreatitis in the rat. Pancreas 1992;7:263-70.
14. Schmidt J, Fernandez-del Castillo C, Rattner DW, Kewandrowski K, Compton CC, Warshaw AL. Trypsinogen activation peptides in experimental rat pancreatitis: prognostic implications and histopathologic correlates. Gastroenterology 1992;103:1009-16.
15. Beechey-Newman N, Simpson K, Sumar N, Jehanli A, Hermon-Taylor J. Trypsinogen activation peptide (TAP) ELIZA demonstrates self-limiting trypsinogen activation in CCK-hyperstimulation pancreatitis in dogs. Pancreas 1993;8:748.
16. Karanjia ND, Widdison AL, Jehanli A, Hermon-Taylor J, Reber HA. Assay of trypsinogen activation in the cat experimental model of acute pancreatitis. Pancreas 1993;8:189-95.
17. Gudgeon AM, Heath DI, Hurley P, et al. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet 1990;335:4-8.
18. Tenner S, Fernandez-del Castillo C, Warshaw AL, et al. Gastroenterology 1995;108:A395.
19. Heath DC, Cruickshank A, Gudgeon AM, Jehanli A, Shenkin A, Imrie CW. The relationship between pancreatic enzyme release and activation and the acute-phase protein response in patients with acute pancreatitis. Pancreas 1195;10: 347-53.
20. Fernandez-del Castillo C, Harringer W, Warshaw AL, et al. Risk factors for pancreatic cellular injury after cardiopulmonary bypass. N Engl J Med 1991;325:382-7.
21. Fiore M, Mitchell J, Doan T, et al. The Abbott IMx Automated Benchtop Immunochemistry Analyzer System. Clin Chem 1988;34:1726-32.
22. Lotveit T, Larsen S, Gronseth K, Osnes M. The probability of pancreatitis after pancreatic parenchymatography with a non-ionic contrast medium. Scand J Gastroenterol 1987;22: 111-6.
23. Bradley EL III. A clinically based classification system for acute pancreatitis. Arch Surg 1993;128:586-90.
24. Balthazar EJ, Robinson DL, Megibow AJ, Ranson JHC. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990;174:331-6.
25. Freeny PC. Incremental dynamic bolus computed tomography of acute pancreatitis. Int J Pancreatol 1993;13:147-58.
26. Karimgani I, Porter KA, Langevin RE, Banks PA. Prognostic factors in sterile pancreatic necrosis. Gastroenterology 1992;103:1636-40.
27. Buchler M, Malfertheiner P, Waldemar U, et al. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993;104:1165-70.